PMID- 29151940
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 17
DP  - 2017
TI  - Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer 
      Metastasis.
PG  - 3548-3554
LID - 10.7150/jca.20535 [doi]
AB  - Background: Given recent results indicating that diminished LKB1 expression in 
      laryngeal cancer correlates with shorter survival. We aim to perform an analysis 
      estimate the role of decreased liver kinase B1(LKB1) and in the prognostication 
      of human laryngeal squamous cell carcinoma (LSCC). Methods: We conducted a 
      retrospective study and evaluate the expression of LKB1 and p16INK4a (p16) in 208 
      clinical advanced-stage LSCC tissue samples by using immunohistochemistry. The 
      specimens were received at Sun Yat-sen University Cancer Center (Guangzhou, 
      China). To evaluate the independent prognostic relevance of LKB1, univariate and 
      multivariate Cox regression models were used, overall survival (OS) and distant 
      metastasis-free survival (DMFS) were compared using the Kaplan-Meier method. 
      Results: Immunohistochemical analyses revealed that 80/208 (38.5%) of the LSCC 
      tissue samples expressed high LKB1. Low LKB1 expression was associated with a 
      significantly shorter OS and DMFS than high LKB1 expression (P = 0.041 and 0.028, 
      respectively; log-rank test), and there was a poorer OS in the p16-positive than 
      p16-negative group. In the subgroup stratified by p16 status, the shorter OS were 
      also seen with low LKB1 expression. Multivariate survival analysis indicated that 
      high LKB1 expression was an independent prognostic factor for OS (hazard ratio 
      [HR]: 1.628, 95% confidence interval [CI]: 1.060-2.500, P = 0.026) and DMFS (HR: 
      2.182, 95% CI: 1.069-4.456, P = 0.032). Conclusions: Our data indicated that low 
      expression of LKB1 was significantly associated with poor prognosis and it may 
      represent a marker of tumor metastasis in patients with LSCC. When combined with 
      p16, LKB1 was also of prognostic value.
FAU - He, Sha-Sha
AU  - He SS
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Radiation, Cancer Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Chen, Yong
AU  - Chen Y
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Radiation, Cancer Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Wang, Hong-Zhi
AU  - Wang HZ
AD  - Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical 
      Science, Peking Union Medical College, Beijing 100021, China.
FAU - Shen, Xiao-Ming
AU  - Shen XM
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Radiology, The First People's Hospital of Foshan (The affiliated 
      Foshan Hospital of Sun Yat-Sen University), Foshan, Guangdong, China.
FAU - Sun, Peng
AU  - Sun P
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Pathology, Cancer Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Dong, Jun
AU  - Dong J
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Liao, Xin-Biao
AU  - Liao XB
AD  - Department of Radiation Oncology, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou, China.
FAU - Guo, Gui-Fang
AU  - Guo GF
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Chen, Ju-Gao
AU  - Chen JG
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
FAU - Xia, Liang-Ping
AU  - Xia LP
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Hu, Pei-Li
AU  - Hu PL
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Qiu, Hui-Juan
AU  - Qiu HJ
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Liu, Shou-Sheng
AU  - Liu SS
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Zhou, Yi-Xin
AU  - Zhou YX
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Wang, Wei
AU  - Wang W
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Gastric Surgery, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
FAU - Hu, Wei-Han
AU  - Hu WH
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of Radiation, Cancer Center, Sun Yat-Sen University, Guangzhou, China.
FAU - Cai, Xiu-Yu
AU  - Cai XY
AD  - State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen 
      University, Guangzhou.
AD  - Department of VIP Region, Cancer Center, Sun Yat-Sen University, Guangzhou, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20170930
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5687170
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - liver kinase B1 (LKB1)
OT  - p16INK4a (p16)
OT  - prognosis.
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2017/11/21 06:00
MHDA- 2017/11/21 06:01
PMCR- 2017/01/01
CRDT- 2017/11/21 06:00
PHST- 2017/04/12 00:00 [received]
PHST- 2017/09/07 00:00 [accepted]
PHST- 2017/11/21 06:00 [entrez]
PHST- 2017/11/21 06:00 [pubmed]
PHST- 2017/11/21 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p3548 [pii]
AID - 10.7150/jca.20535 [doi]
PST - epublish
SO  - J Cancer. 2017 Sep 30;8(17):3548-3554. doi: 10.7150/jca.20535. eCollection 2017.